Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives - PubMed
4 days ago
- #Cancer Treatment
- #Immunotherapy
- #Nanomedicine
- Adoptive cell therapy (ACT) has shown significant success in treating hematologic malignancies through T cell engineering with chimeric antigen receptors (CAR).
- Solid tumors present challenges for ACT due to barriers like tumor-specific antigen scarcity, immunosuppressive microenvironments, and dense extracellular matrices.
- Nanoparticle (NP)-based approaches enhance ACT by improving tumor immunogenicity, vascular permeability, and reducing off-target toxicity.
- Strategies include NP delivery of immunomodulators, chemotherapeutics, hyperthermia, magnetic guidance for T cell accumulation, and in vivo CAR T cell generation.
- Environmental impact assessments are crucial for sustainable nanomedicine development.
- Future research directions focus on safety, sustainability, and overcoming current challenges in NP-enhanced ACT.